Pharmaceutical Contract Sales Outsourcing (CSO) Market (Therapeutic Area: Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others) - Europe Industry Analysis, Size, Share, Growth, Trends, an

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,795	181 Pages	Transparency Market Research Pvt. Ltd.	July, 2022	TNPR17372899

Best Price Guarantee
Price	from $5,795
Length	181 Pages
Publisher	Transparency Market Research Pvt. Ltd.
Published Date	July, 2022
SKU	TNPR17372899

Pharmaceutical Contract Sales Outsourcing (CSO) Market (Therapeutic Area: Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others) - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market – Scope of Report
TMR’s report on the pharmaceutical contract sales outsourcing (CSO) market in Europe studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the pharmaceutical contract sales outsourcing (CSO) market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of pharmaceutical contract sales outsourcing (CSO) market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the pharmaceutical contract sales outsourcing (CSO) market in Europe.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the pharmaceutical contract sales outsourcing (CSO) market in Europe.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the pharmaceutical contract sales outsourcing (CSO) market in Europe. These serve as valuable tools for existing market players as well as for entities interested in participating in the pharmaceutical contract sales outsourcing (CSO) market in Europe.

The report delves into the competitive landscape of the pharmaceutical contract sales outsourcing (CSO) market. Key players operating in the pharmaceutical contract sales outsourcing (CSO) market in Europe have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the pharmaceutical contract sales outsourcing (CSO) market profiled in this report.

Research Methodology
The research methodology is a combination of exhaustive primary and secondary research to analyze the pharmaceutical contract sales outsourcing (CSO) market.

Secondary Research

Secondary research included a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we referred to include, but are not limited to:

Company websites, presentations, annual reports, white papers, technical papers, product brochures
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
Veterinary Council of Europe
Europen Federation of Animal Health
Animal Welfare Board of Europe
Company Information
Statista
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of the research, we conducted in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents the bulk of research efforts, supplemented by extensive secondary research.

We conducted primary interviews with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who took part in the process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts
Key opinion leaders specializing in the market with respect to different industry verticals
Primary participants included, but are not limited to:

Bayer AG
Elanco Products Company
Merck & Co., Inc.
Ceva Sante Animale
Virbac SA

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter

Market Estimation: Market size estimations involved an in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we used modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Population, inflation rates, and others
Industry Indicators: Production data, R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived by taking into account drivers, restraints/challenges, opportunities prevailing in the market, and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise consumption data are the other pivotal factors considered to derive market forecasts.

1. Preface: 1.1. Market Definition and Scope; 1.2. Market Segmentation; 1.3. Key Research Objectives; 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market
4. Market Overview: 4.1. Introduction; 4.1.1. Market Introduction; 4.2. Overview; 4.3. Market Dynamics; 4.3.1. Drivers; 4.3.2. Restraints; 4.3.3. Opportunities; 4.4. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, 2017–2031; 4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights: 5.1. Europe Healthcare Industry Overview; 5.2. Key Industry Events (mergers, acquisitions, partnerships, etc.); 5.3. COVID-19 Pandemic Impact on Industry (value chain and short /mid / long term impact)
6. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Service: 6.1. Introduction & Definition; 6.2. Key Findings / Developments; 6.3. Market Value Forecast, by Service, 2017–2031; 6.3.1. Personal Promotion; 6.3.1.1. Promotional Sales Team; 6.3.1.1.1. Dedicated Sales Team; 6.3.1.1.2. Syndicated Sales Team; 6.3.1.2. Key Account Management; 6.3.1.3. Vacancy Management; 6.3.2. Non-personal Promotion; 6.3.2.1. Tele-detailing; 6.3.2.2. Interactive E-detailing; 6.3.2.3. Customer Service; 6.3.2.4. Medical Science Liaisons; 6.3.2.5. Patient Engagement Services; 6.3.2.6. Others; 6.3.3. Other Services; 6.4. Market Attractiveness Analysis, by Service
7. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Therapeutic Area: 7.1. Introduction & Definition; 7.2. Key Findings / Developments; 7.3. Market Value Forecast, by Therapeutic Area, 2017–2031; 7.3.1. Cardiovascular Disorders; 7.3.2. Oncology; 7.3.3. Metabolic Disorders; 7.3.4. Neurology; 7.3.5. Orthopedic Diseases; 7.3.6. Infectious Diseases; 7.3.7. Others; 7.4. Market Attractiveness Analysis, by Therapeutic Area
8. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Region: 8.1. Key Findings; 8.2. Market Value Forecast, by Region; 8.2.1. Germany; 8.2.2. U.K.; 8.2.3. France; 8.2.4. Italy; 8.2.5. Spain; 8.2.6. Rest of Europe; 8.3. Market Attractiveness Analysis, by Country/Sub-region
9. Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast: 9.1. Introduction; 9.1.1. Key Findings; 9.2. Market Value Forecast, by Service, 2017–2031; 9.2.1. Personal Promotion; 9.2.1.1. Promotional Sales Team; 9.2.1.1.1. Dedicated Sales Team; 9.2.1.1.2. Syndicated Sales Team; 9.2.1.2. Key Account Management; 9.2.1.3. Vacancy Management; 9.2.2. Non-personal Promotion; 9.2.2.1. Tele-detailing; 9.2.2.2. Interactive E-detailing; 9.2.2.3. Customer Service; 9.2.2.4. Medical Science Liaisons; 9.2.2.5. Patient Engagement Services; 9.2.2.6. Others; 9.2.3. Other Services; 9.3. Market Value Forecast, by Therapeutic Area, 2017–2031; 9.3.1. Cardiovascular Disorders; 9.3.2. Oncology; 9.3.3. Metabolic Disorders; 9.3.4. Neurology; 9.3.5. Orthopedic Diseases; 9.3.6. Infectious Diseases; 9.3.7. Others; 9.4. Market Attractiveness Analysis; 9.4.1. By Service; 9.4.2. By Therapeutic Area
10. U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast: 10.1. Introduction; 10.1.1. Key Findings; 10.2. Market Value Forecast, by Service, 2017–2031; 10.2.1. Personal Promotion; 10.2.1.1. Promotional Sales Team; 10.2.1.1.1. Dedicated Sales Team; 10.2.1.1.2. Syndicated Sales Team; 10.2.1.2. Key Account Management; 10.2.1.3. Vacancy Management; 10.2.2. Non-personal Promotion; 10.2.2.1. Tele-detailing; 10.2.2.2. Interactive E-detailing; 10.2.2.3. Customer Service; 10.2.2.4. Medical Science Liaisons; 10.2.2.5. Patient Engagement Services; 10.2.2.6. Others; 10.2.3. Other Services; 10.3. Market Value Forecast, by Therapeutic Area, 2017–2031; 10.3.1. Cardiovascular Disorders; 10.3.2. Oncology; 10.3.3. Metabolic Disorders; 10.3.4. Neurology; 10.3.5. Orthopedic Diseases; 10.3.6. Infectious Diseases; 10.3.7. Others; 10.4. Market Attractiveness Analysis; 10.4.1. By Service; 10.4.2. By Therapeutic Area
11. France Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast: 11.1. Introduction; 11.1.1. Key Findings; 11.2. Market Value Forecast, by Service, 2017–2031; 11.2.1. Personal Promotion; 11.2.1.1. Promotional Sales Team; 11.2.1.1.1. Dedicated Sales Team; 11.2.1.1.2. Syndicated Sales Team; 11.2.1.2. Key Account Management; 11.2.1.3. Vacancy Management; 11.2.2. Non-personal Promotion; 11.2.2.1. Tele-detailing; 11.2.2.2. Interactive E-detailing; 11.2.2.3. Customer Service; 11.2.2.4. Medical Science Liaisons; 11.2.2.5. Patient Engagement Services; 11.2.2.6. Others; 11.2.3. Other Services; 11.3. Market Value Forecast, by Therapeutic Area, 2017–2031; 11.3.1. Cardiovascular Disorders; 11.3.2. Oncology; 11.3.3. Metabolic Disorders; 11.3.4. Neurology; 11.3.5. Orthopedic Diseases; 11.3.6. Infectious Diseases; 11.3.7. Others; 11.4. Market Attractiveness Analysis; 11.4.1. By Service; 11.4.2. Therapeutic Area
12. Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast: 12.1. Introduction; 12.1.1. Key Findings; 12.2. Market Value Forecast, by Service, 2017–2031; 12.2.1. Personal Promotion; 12.2.1.1. Promotional Sales Team; 12.2.1.1.1. Dedicated Sales Team; 12.2.1.1.2. Syndicated Sales Team; 12.2.1.2. Key Account Management; 12.2.1.3. Vacancy Management; 12.2.2. Non-personal Promotion; 12.2.2.1. Tele-detailing; 12.2.2.2. Interactive E-detailing; 12.2.2.3. Customer Service; 12.2.2.4. Medical Science Liaisons; 12.2.2.5. Patient Engagement Services; 12.2.2.6. Others; 12.2.3. Other Services; 12.3. Market Value Forecast, by Therapeutic Area, 2017–2031; 12.3.1. Cardiovascular Disorders; 12.3.2. Oncology; 12.3.3. Metabolic Disorders; 12.3.4. Neurology; 12.3.5. Orthopedic Diseases; 12.3.6. Infectious Diseases; 12.3.7. Others; 12.4. Market Attractiveness Analysis; 12.4.1. By Service; 12.4.2. By Therapeutic Area
13. Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast: 13.1. Introduction; 13.1.1. Key Findings; 13.2. Market Value Forecast, by Service, 2017–2031; 13.2.1. Personal Promotion; 13.2.1.1. Promotional Sales Team; 13.2.1.1.1. Dedicated Sales Team; 13.2.1.1.2. Syndicated Sales Team; 13.2.1.2. Key Account Management; 13.2.1.3. Vacancy Management; 13.2.2. Non-personal Promotion; 13.2.2.1. Tele-detailing; 13.2.2.2. Interactive E-detailing; 13.2.2.3. Customer Service; 13.2.2.4. Medical Science Liaisons; 13.2.2.5. Patient Engagement Services; 13.2.2.6. Others; 13.2.3. Other Services; 13.3. Market Value Forecast, by Therapeutic Area, 2017–2031; 13.3.1. Cardiovascular Disorders; 13.3.2. Oncology; 13.3.3. Metabolic Disorders; 13.3.4. Neurology; 13.3.5. Orthopedic Diseases; 13.3.6. Infectious Diseases; 13.3.7. Others; 13.4. Market Attractiveness Analysis; 13.4.1. By Service; 13.4.2. By Therapeutic Area
14. Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast: 14.1. Introduction; 14.1.1. Key Findings; 14.2. Market Value Forecast, by Service, 2017–2031; 14.2.1. Personal Promotion; 14.2.1.1. Promotional Sales Team; 14.2.1.1.1. Dedicated Sales Team; 14.2.1.1.2. Syndicated Sales Team; 14.2.1.2. Key Account Management; 14.2.1.3. Vacancy Management; 14.2.2. Non-personal Promotion; 14.2.2.1. Tele-detailing; 14.2.2.2. Interactive E-detailing; 14.2.2.3. Customer Service; 14.2.2.4. Medical Science Liaisons; 14.2.2.5. Patient Engagement Services; 14.2.2.6. Others; 14.2.3. Other Services; 14.3. Market Value Forecast, by Therapeutic Area, 2017–2031; 14.3.1. Cardiovascular Disorders; 14.3.2. Oncology; 14.3.3. Metabolic Disorders; 14.3.4. Neurology; 14.3.5. Orthopedic Diseases; 14.3.6. Infectious Diseases; 14.3.7. Others; 14.4. Market Attractiveness Analysis; 14.4.1. By Service; 14.4.2. By Therapeutic Area
15. Competition Landscape: 15.1. Market Player - Competition Matrix (by tier and size of companies); 15.2. Market Share Analysis/Ranking, by Company, 2021; 15.3. Company Profiles; 15.3.1. Ashfield (UDG Healthcare plc); 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength); 15.3.1.2. Company Financials; 15.3.1.3. Growth Strategies; 15.3.1.4. SWOT Analysis; 15.3.2. Syneos Health; 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength); 15.3.2.2. Company Financials; 15.3.2.3. Growth Strategies; 15.3.2.4. SWOT Analysis; 15.3.3. IQVIA, Inc.; 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength); 15.3.3.2. Company Financials; 15.3.3.3. Growth Strategies; 15.3.3.4. SWOT Analysis; 15.3.4. GTS Solution; 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength); 15.3.4.2. Company Financials; 15.3.4.3. Growth Strategies; 15.3.4.4. SWOT Analysis; 15.3.5. EVERSANA; 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength); 15.3.5.2. Company Financials; 15.3.5.3. Growth Strategies; 15.3.5.4. SWOT Analysis; 15.3.6. MaBiCo; 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength); 15.3.6.2. Company Financials; 15.3.6.3. Growth Strategies; 15.3.6.4. SWOT Analysis; 15.3.7. Pharmaforce Ireland Ltd.; 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength); 15.3.7.2. Company Financials; 15.3.7.3. Growth Strategies; 15.3.7.4. SWOT Analysis; 15.3.8. Sales Focus, Inc.; 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength); 15.3.8.2. Company Financials; 15.3.8.3. Growth Strategies; 15.3.8.4. SWOT Analysis; 15.3.9. Amplity Health; 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength); 15.3.9.2. Company Financials; 15.3.9.3. Growth Strategies; 15.3.9.4. SWOT Analysis; 15.3.10. PharmaLex GmbH; 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength); 15.3.10.2. Company Financials; 15.3.10.3. Growth Strategies; 15.3.10.4. SWOT Analysis; 15.3.11. Star OUTiCO; 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength); 15.3.11.2. Company Financials; 15.3.11.3. Growth Strategies; 15.3.11.4. SWOT Analysis; 15.3.12. NiSiPharm GmbH; 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength); 15.3.12.2. Company Financials; 15.3.12.3. Growth Strategies; 15.3.12.4. SWOT Analysis